TW202123942A - Ｂｒｄ９雙官能基降解劑及其使用方法 - Google Patents

Ｂｒｄ９雙官能基降解劑及其使用方法 Download PDF

Info

Publication number
TW202123942A
TW202123942A TW109131573A TW109131573A TW202123942A TW 202123942 A TW202123942 A TW 202123942A TW 109131573 A TW109131573 A TW 109131573A TW 109131573 A TW109131573 A TW 109131573A TW 202123942 A TW202123942 A TW 202123942A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
formula
compound
alkylene
Prior art date
Application number
TW109131573A
Other languages
English (en)
Chinese (zh)
Inventor
昕 陳
愛得蒙 馬汀 哈林頓
格勾利 約翰 豪林沃斯
瑪麗 蘭 戈德
茱莉安 羅柏
安娜 沃佩提
馬汀 珊蒂斯克
湯瑪斯 佐勒
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72915891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202123942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202123942A publication Critical patent/TW202123942A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109131573A 2019-09-16 2020-09-14 Ｂｒｄ９雙官能基降解劑及其使用方法 TW202123942A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962900869P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US201962900863P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
US62/900,860 2019-09-16
US62/900,863 2019-09-16
US62/900,869 2019-09-16
US62/900,865 2019-09-16

Publications (1)

Publication Number Publication Date
TW202123942A true TW202123942A (zh) 2021-07-01

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109131573A TW202123942A (zh) 2019-09-16 2020-09-14 Ｂｒｄ９雙官能基降解劑及其使用方法

Country Status (21)

Country Link
US (1) US20220315578A1 (enExample)
EP (1) EP4041724A1 (enExample)
JP (1) JP2022547952A (enExample)
KR (1) KR20220063192A (enExample)
CN (1) CN114641473A (enExample)
AU (1) AU2020349451B2 (enExample)
BR (1) BR112022003514A2 (enExample)
CA (1) CA3153529A1 (enExample)
CO (1) CO2022002842A2 (enExample)
CR (1) CR20220105A (enExample)
DO (1) DOP2022000053A (enExample)
EC (1) ECSP22018571A (enExample)
IL (1) IL290677A (enExample)
JO (1) JOP20220069A1 (enExample)
MX (1) MX2022003102A (enExample)
PE (1) PE20221417A1 (enExample)
PH (1) PH12022550611A1 (enExample)
PY (1) PY2054376A (enExample)
TW (1) TW202123942A (enExample)
UY (1) UY38880A (enExample)
WO (1) WO2021055295A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236172A (zh) 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4031247A1 (en) * 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
TWI873185B (zh) 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
MX2022009308A (es) 2020-01-29 2022-08-22 Foghorn Therapeutics Inc Compuestos y usos de estos.
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
CN115806547A (zh) * 2021-09-09 2023-03-17 C4医药公司 选择的用于brd9的靶向降解的化合物
CN118339151A (zh) * 2021-12-15 2024-07-12 西藏海思科制药有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
WO2024163609A1 (en) * 2023-02-01 2024-08-08 Foghorn Therapeutics Inc. Compositions for treating cancer
JP2026519523A (ja) 2023-05-24 2026-06-16 ビアクティカ セラピューティクス エービー Ｔｅａｄへの結合剤としての芳香族アミドおよびそのコンジュゲート
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
WO2025256550A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 靶向降解剂配体及连接基的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3265453B1 (en) * 2015-03-05 2022-06-29 Boehringer Ingelheim International GmbH New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
US11285218B2 (en) * 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
IL319363A (en) * 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
US11065231B2 (en) * 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
CN111491933A (zh) * 2017-12-18 2020-08-04 豪夫迈·罗氏有限公司 具有e3泛素连接酶部分的egfr双功能抑制剂
US11512080B2 (en) * 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CN111936501B (zh) * 2018-03-26 2023-09-22 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
EP3774804A1 (en) * 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3917517A4 (en) * 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
WO2020160192A1 (en) * 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof

Also Published As

Publication number Publication date
KR20220063192A (ko) 2022-05-17
CA3153529A1 (en) 2021-03-25
EP4041724A1 (en) 2022-08-17
US20220315578A1 (en) 2022-10-06
IL290677A (en) 2022-04-01
WO2021055295A1 (en) 2021-03-25
JP2022547952A (ja) 2022-11-16
MX2022003102A (es) 2022-04-06
ECSP22018571A (es) 2022-04-29
CN114641473A (zh) 2022-06-17
DOP2022000053A (es) 2023-01-31
BR112022003514A2 (pt) 2022-05-17
CR20220105A (es) 2022-06-13
CO2022002842A2 (es) 2022-04-19
UY38880A (es) 2021-04-30
PE20221417A1 (es) 2022-09-20
JOP20220069A1 (ar) 2023-01-30
AU2020349451A1 (en) 2022-04-21
PY2054376A (es) 2021-09-07
AU2020349451B2 (en) 2024-02-01
PH12022550611A1 (en) 2023-03-13

Similar Documents

Publication Publication Date Title
CN114641473A (zh) Brd9双官能团降解剂及其使用方法
JP7717202B2 (ja) ヒトインテグリン（アルファ－４）（ベータ－７）の阻害
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
TWI663153B (zh) 作為激酶抑制劑的胺基雜芳基苯甲醯胺
WO2024083258A1 (zh) Kras g12d降解剂及其制备方法和应用
WO2021052499A1 (zh) 稠合吡啶酮类化合物及其制备方法和应用
TWI534144B (zh) 甲狀腺荷爾蒙β受體作動藥
CN104812748B (zh) 二氢吡唑gpr40调节剂
CN103097364B (zh) 作为s1p调节剂的螺-哌啶衍生物
CN114521196A (zh) 双官能团降解剂及其使用方法
CN104918935B (zh) 二氢吡唑gpr40调节剂
TW201726606A (zh) 作為免疫調節劑之化合物
TWI781342B (zh) KEAP1-Nrf2蛋白-蛋白交互作用抑制劑
TW201630904A (zh) 經取代之烷及其使用方法
TW201414737A (zh) 作爲激酶抑制劑之咪唑并三□甲腈
JP6954921B2 (ja) ブロモドメイン阻害薬としてのピリジル誘導体
TW201702215A (zh) 人類免疫不全病毒複製之抑制劑
TW201706275A (zh) 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
CN104583196A (zh) 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN106164076A (zh) 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
JP2018526383A (ja) ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
JP2019516761A (ja) ブロモドメイン阻害薬としてのピリジンジカルボキサミド誘導体
WO2025108255A1 (zh) 一种多环类衍生物、其制备方法和应用
TWI743088B (zh) 作爲免疫調節劑的三並環化合物
TW202430522A (zh) 一種用於ｂｃｌ－２蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用